Impact of Treatment With VENARUS® on the Level of Monocyte Chemoattractant Protein 1 in Varicose Veins Blood
Varicose Veins
About this trial
This is an interventional basic science trial for Varicose Veins
Eligibility Criteria
Inclusion Criteria:
• both female and male
- age from 18 to 50 years old
- Verified diagnosis of chronic venous insufficiency CEAP C2-C4
- signed infromed consent
- Absence of any other treatment 2 weeks before the start of the study and throughout the duration of the study
Exclusion Criteria:
• age less than 18 and more than 50 years
- Previously performed invasive interventions for varicose veins on any of the lower extremities
- No visible varicose veins
- Thrombophlebitis and deep vein thrombosis of the lower extremities in the past
- Taking prohibited pre-trial therapy
- Contraindications to taking Venarus®
- not signed informed consent
Sites / Locations
- Pirogov Russian National Research Medical University
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
study group
control group
Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein before and after administration of Venarus® (100 mg hesperidin + 900 mg diosmin) for 2 months
Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr vein. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein at inclusion and 2 months later/